U.S., May 31 -- ClinicalTrials.gov registry received information related to the study (NCT06996912) titled 'A Study for HSK44459 in Participants With Atopic Dermatitis' on May 21.
Brief Summary: The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis
Study Start Date: May 26
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis (AD)
Intervention:
DRUG: HSK44459
HSK44459 will be administered orally twice daily
DRUG: Placebo
Placebo will be administered orally twice daily
Recruitment Status: RECRUITING
Sponsor: Xizang Haisco Pharmaceutical Co., Ltd
Disclaimer: Curated by HT Syndication....